Accelerated progression of chronic lymphocytic leukemia in Em-TCL1 mice expressing catalytically inactive RAG1

Vincent K. Nganga, Victoria L. Palmer, Hina Naushad Qureishi, Michele D. Kassmeier, Dirk K. Anderson, Greg A. Perry, Nathan M. Schabla, Patrick C. Swanson

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia (CLL) is a prevalent B-cell neoplasia that is often preceded by a more benign monoclonal CD51 B-cell lymphocytosis. We previously generated transgenic mice expressing catalytically inactive RAG1 (dominant-negative recombination activating gene 1 [dnRAG1] mice) that develop an early-onset indolent CD51 B-cell lymphocytosis attributed to a defect in secondary V(D)J rearrangements initiated to edit autoreactive B-cell receptor (BCR) specificity. Hypothesizing that CD51 B cells in these animals represent potential CLL precursors, we crossed dnRAG1 mice with CLL-prone Em-TCL1 mice to determine whether dnRAG1 expression in Em-TCL1 mice accelerates CLL onset. Consistent with this hypothesis, CD51 B-cell expansion and CLL progression occurred more rapidly in double-transgenic mice compared with Em-TCL1 mice. Nevertheless, CD51 B cells in the 2 mouse strains exhibited close similarities in phenotype, im-munoglobulin gene usage, and mutation status, and expression of genes associated with immune tolerance and BCR signaling. Gene expression profiling further revealed a potential role for prolactin signaling in regulating BCR editing. These results suggest a model in which benign accumulation of CD51 B cells can be initiated through a failure to successfully edit autoreactive BCR specificity and may, in turn, progress to CLL upon introduction of additional genetic mutations.

Original languageEnglish (US)
Pages (from-to)3855-3866
Number of pages12
JournalBlood
Volume121
Issue number19
DOIs
StatePublished - May 9 2013

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Cells
RAG-1 Genes
Genes
Lymphocytosis
Transgenic Mice
Gene Expression
Immune Tolerance
Mutation
Gene expression
Prolactin
Gene Expression Profiling
Animals
Defects
Phenotype

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Nganga, V. K., Palmer, V. L., Naushad Qureishi, H., Kassmeier, M. D., Anderson, D. K., Perry, G. A., ... Swanson, P. C. (2013). Accelerated progression of chronic lymphocytic leukemia in Em-TCL1 mice expressing catalytically inactive RAG1. Blood, 121(19), 3855-3866. https://doi.org/10.1182/blood-2012-08-446732

Accelerated progression of chronic lymphocytic leukemia in Em-TCL1 mice expressing catalytically inactive RAG1. / Nganga, Vincent K.; Palmer, Victoria L.; Naushad Qureishi, Hina; Kassmeier, Michele D.; Anderson, Dirk K.; Perry, Greg A.; Schabla, Nathan M.; Swanson, Patrick C.

In: Blood, Vol. 121, No. 19, 09.05.2013, p. 3855-3866.

Research output: Contribution to journalArticle

Nganga, VK, Palmer, VL, Naushad Qureishi, H, Kassmeier, MD, Anderson, DK, Perry, GA, Schabla, NM & Swanson, PC 2013, 'Accelerated progression of chronic lymphocytic leukemia in Em-TCL1 mice expressing catalytically inactive RAG1', Blood, vol. 121, no. 19, pp. 3855-3866. https://doi.org/10.1182/blood-2012-08-446732
Nganga, Vincent K. ; Palmer, Victoria L. ; Naushad Qureishi, Hina ; Kassmeier, Michele D. ; Anderson, Dirk K. ; Perry, Greg A. ; Schabla, Nathan M. ; Swanson, Patrick C. / Accelerated progression of chronic lymphocytic leukemia in Em-TCL1 mice expressing catalytically inactive RAG1. In: Blood. 2013 ; Vol. 121, No. 19. pp. 3855-3866.
@article{1fa2dbe6855d420ba6d78c93c9c19173,
title = "Accelerated progression of chronic lymphocytic leukemia in Em-TCL1 mice expressing catalytically inactive RAG1",
abstract = "Chronic lymphocytic leukemia (CLL) is a prevalent B-cell neoplasia that is often preceded by a more benign monoclonal CD51 B-cell lymphocytosis. We previously generated transgenic mice expressing catalytically inactive RAG1 (dominant-negative recombination activating gene 1 [dnRAG1] mice) that develop an early-onset indolent CD51 B-cell lymphocytosis attributed to a defect in secondary V(D)J rearrangements initiated to edit autoreactive B-cell receptor (BCR) specificity. Hypothesizing that CD51 B cells in these animals represent potential CLL precursors, we crossed dnRAG1 mice with CLL-prone Em-TCL1 mice to determine whether dnRAG1 expression in Em-TCL1 mice accelerates CLL onset. Consistent with this hypothesis, CD51 B-cell expansion and CLL progression occurred more rapidly in double-transgenic mice compared with Em-TCL1 mice. Nevertheless, CD51 B cells in the 2 mouse strains exhibited close similarities in phenotype, im-munoglobulin gene usage, and mutation status, and expression of genes associated with immune tolerance and BCR signaling. Gene expression profiling further revealed a potential role for prolactin signaling in regulating BCR editing. These results suggest a model in which benign accumulation of CD51 B cells can be initiated through a failure to successfully edit autoreactive BCR specificity and may, in turn, progress to CLL upon introduction of additional genetic mutations.",
author = "Nganga, {Vincent K.} and Palmer, {Victoria L.} and {Naushad Qureishi}, Hina and Kassmeier, {Michele D.} and Anderson, {Dirk K.} and Perry, {Greg A.} and Schabla, {Nathan M.} and Swanson, {Patrick C.}",
year = "2013",
month = "5",
day = "9",
doi = "10.1182/blood-2012-08-446732",
language = "English (US)",
volume = "121",
pages = "3855--3866",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

TY - JOUR

T1 - Accelerated progression of chronic lymphocytic leukemia in Em-TCL1 mice expressing catalytically inactive RAG1

AU - Nganga, Vincent K.

AU - Palmer, Victoria L.

AU - Naushad Qureishi, Hina

AU - Kassmeier, Michele D.

AU - Anderson, Dirk K.

AU - Perry, Greg A.

AU - Schabla, Nathan M.

AU - Swanson, Patrick C.

PY - 2013/5/9

Y1 - 2013/5/9

N2 - Chronic lymphocytic leukemia (CLL) is a prevalent B-cell neoplasia that is often preceded by a more benign monoclonal CD51 B-cell lymphocytosis. We previously generated transgenic mice expressing catalytically inactive RAG1 (dominant-negative recombination activating gene 1 [dnRAG1] mice) that develop an early-onset indolent CD51 B-cell lymphocytosis attributed to a defect in secondary V(D)J rearrangements initiated to edit autoreactive B-cell receptor (BCR) specificity. Hypothesizing that CD51 B cells in these animals represent potential CLL precursors, we crossed dnRAG1 mice with CLL-prone Em-TCL1 mice to determine whether dnRAG1 expression in Em-TCL1 mice accelerates CLL onset. Consistent with this hypothesis, CD51 B-cell expansion and CLL progression occurred more rapidly in double-transgenic mice compared with Em-TCL1 mice. Nevertheless, CD51 B cells in the 2 mouse strains exhibited close similarities in phenotype, im-munoglobulin gene usage, and mutation status, and expression of genes associated with immune tolerance and BCR signaling. Gene expression profiling further revealed a potential role for prolactin signaling in regulating BCR editing. These results suggest a model in which benign accumulation of CD51 B cells can be initiated through a failure to successfully edit autoreactive BCR specificity and may, in turn, progress to CLL upon introduction of additional genetic mutations.

AB - Chronic lymphocytic leukemia (CLL) is a prevalent B-cell neoplasia that is often preceded by a more benign monoclonal CD51 B-cell lymphocytosis. We previously generated transgenic mice expressing catalytically inactive RAG1 (dominant-negative recombination activating gene 1 [dnRAG1] mice) that develop an early-onset indolent CD51 B-cell lymphocytosis attributed to a defect in secondary V(D)J rearrangements initiated to edit autoreactive B-cell receptor (BCR) specificity. Hypothesizing that CD51 B cells in these animals represent potential CLL precursors, we crossed dnRAG1 mice with CLL-prone Em-TCL1 mice to determine whether dnRAG1 expression in Em-TCL1 mice accelerates CLL onset. Consistent with this hypothesis, CD51 B-cell expansion and CLL progression occurred more rapidly in double-transgenic mice compared with Em-TCL1 mice. Nevertheless, CD51 B cells in the 2 mouse strains exhibited close similarities in phenotype, im-munoglobulin gene usage, and mutation status, and expression of genes associated with immune tolerance and BCR signaling. Gene expression profiling further revealed a potential role for prolactin signaling in regulating BCR editing. These results suggest a model in which benign accumulation of CD51 B cells can be initiated through a failure to successfully edit autoreactive BCR specificity and may, in turn, progress to CLL upon introduction of additional genetic mutations.

UR - http://www.scopus.com/inward/record.url?scp=84880474898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880474898&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-08-446732

DO - 10.1182/blood-2012-08-446732

M3 - Article

C2 - 23502221

AN - SCOPUS:84880474898

VL - 121

SP - 3855

EP - 3866

JO - Blood

JF - Blood

SN - 0006-4971

IS - 19

ER -